Results 91 to 100 of about 50,320 (220)

Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension

Saudi Journal of Kidney Diseases and Transplantation, 2011
To determine the antihypertensive benefit of adding low dose sprinolactone to multi-drug regimens that included a diuretic, a calcium channel blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with moderately ...
Rozita Abolghasmi, Omolbanin Taziki
doaj  

Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes [PDF]

, 2020
Skander Mulder, Paul Perco, Christina Stolzenburg Oxlund, Uzma F. Mehdi, Thomas Hankemeier, Ib Abildgaard Jacobsen, Robert D. Toto, Hiddo J.L. Heerspink, Michelle J. Pena   +8 more
openalex   +1 more source

GAMBARAN PERESEPAN SPIRONOLACTONE PADA PASIEN GAGAL JANTUNG DI RSUP DR KARIADI SEMARANG [PDF]

, 2015
Background Heart failure is a clinical syndrome caused by abnormalities of cardiac structure or function. A condition when the heart as a pump can’t fulfill body’s blood demand to keep tissue’s metabolism well.
Anggriyani, Novi, Ksatria, Feby Tegar
core   +1 more source

P2501Rivaroxaban combined with spironolactone attenuates cardiovascular remodeling due to hypoxia in pulmonary arterial hypertension [PDF]

, 2018
Tatsuya Hayashi, Sen Matsumoto, Akiyo Hosokawa, Kazutoshi Yamamoto, Atsuo Nomura, Eiki Woo, Hideki Imano, Ryuji Kato, Yoshio Ijiri, Takehiro Yamaguchi, Yoko Izumi, M. Yoshiyama, Yasunori Okada, Michio Asahi   +13 more
openalex   +1 more source

Toxic epidermal necrolysis associated with combination therapy of spironolactone and torsemide

, 2020
Melcy Mary Philip, Kala Kesavan P, Jai Prakash   +2 more
openalex   +1 more source

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol

Canadian Journal of Kidney Health and Disease
Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. Whether spironolactone, a mineralocorticoid receptor antagonist, improves outcomes for patients
Michael Walsh, David Collister, Martin Gallagher, Patrick B. Mark, Janak R. de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Laura Sola, Gilmar Reis, Denis Xavier, Russell Villanueva, Wen J. Liu, Camilo Félix, Li Zuo, Mustafa Arici, Vivekanand Jha, Ron Wald, Amanda Y. Wang, Atiya R. Faruqui, Fei Yuan, Shun Fu Lee, Alena Kuptsova, Courtney Christou, P. J. Devereaux,   +24 more
doaj   +1 more source

Let's (not) Get Physical: the Effect of Spironolactone on Muscle Strength in the Elderly

, 2014
Europe PMC Team
openalex   +1 more source

Is it time for spironolactone therapy in dialysis patients? [PDF]

, 2006
Adrian Covic, Paul Gusbeth–Tatomir, David Goldsmith   +2 more
openalex   +1 more source

A comparison of some extra‐renal effects of spironolactone and canrenone. [PDF]

, 1979
G. Huston, Al-Dujaili Ea
openalex   +1 more source

SAT379 Potassium Levels in Women with PCOS Using Spironolactone for Long-term [PDF]

, 2023
Thais Areias Oliveira, Lucas Bandeira Marchesan, Poli Mara Spritzer   +2 more
openalex   +1 more source